The Liver Graft Before Transplantation: Defining Outcome After Liver Transplantation provides a comprehensive overview of pretransplant assessment and conditioning of liver grafts to guide the best strategy for successful transplantation and better outcomes for patients. Sections provide an overview of the history and indications for liver transplantations as well as coverage of current practices used in transplantation. Next, donor and liver graft assessment are discussed with specific coverage of diseases that carry a risk of recurrence after liver transplantation, including hepatocellular carcinoma, NASH, primary biliary cholangitis, primary sclerosing cholangitis, and viral hepatitis.
Finally, the impact of the use of suboptimal liver grafts and clues to make the right trade-off between benefit and risk are discussed. This is the perfect reference for clinicians who need a comprehensive, clinically relevant overview of pretransplant assessment and conditioning of liver grafts and want to know what to expect in future years.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Section One: Liver transplantation1. Introduction, history
2. Current practice
3. Outcome
4. Living donation in liver transplantation
Section Two: Assessment of a liver graft
1. Assessment of a donor
2. Assessment of a liver graft
3. Risk related to a suboptimal liver graft
4. Liver procurement; DBD, DCD, living donation
5. The use of machine perfusion in liver transplantation
6. Emerging treatments in graft reconditioning beyond machine perfusion
Authors
Xavier Verhelst Senior Hepatologist, Gastrointestinal and Liver Diseases Department, Ghent University Hospital, Belgium.Prof. Dr. Xavier Verhelst, MD, PhD, is a senior hepatologist at the Gastrointestinal and Liver Diseases Department at Ghent University Hospital. Dr. Verhelst is a member of the Global PBC Study Group for primary biliary cholangitis, the International PSC Study Group for primary sclerosing cholangitis (iPSCsg), and the Vascular Liver Disease Group (VALDIG) for vascular liver disease. He has been involved as a primary or subinvestigator in numerous phase I, II, and III clinical studies for new therapies in patients with viral hepatitis, primary liver tumors, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis, and liver transplantation. He has given lectures at national and international conferences. He is the author and coauthor of more than 100 peer-reviewed publications. He is a member of the Board of the Flemish Association for Gastroenterology and a member of the Belgian Association for the Study of the Liver, the European Association for the Study of the Liver (EASL), and Belgian Transplant Association.
